
Merck: CMV inhibitor Premin launched in China
On August 5, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Premin® (Litemovir Tablets), was officially launched in China for patients undergoing allogeneic hematopoietic
On August 5, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Premin® (Litemovir Tablets), was officially launched in China for patients undergoing allogeneic hematopoietic